
Sarah E Seton-Rogers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4167008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cooperation of the ErbB2 receptor and transforming growth factor in induction of migration and invasion in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1257-1262.	7.1	222
2	Delving deeper into resistance. Nature Reviews Cancer, 2014, 14, 7-7.	28.4	157
3	Untangling EMT's functions. Nature Reviews Cancer, 2016, 16, 1-1.	28.4	57
4	Multitasking hyaluronic acid. Nature Reviews Cancer, 2012, 12, 228-228.	28.4	19
5	The cancer X factor. Nature Reviews Cancer, 2013, 13, 224-225.	28.4	19
6	Gender differences. Nature Reviews Cancer, 2014, 14, 579-579.	28.4	18
7	VEGF promotes stemness. Nature Reviews Cancer, 2011, 11, 831-831.	28.4	16
8	siRNAs jump the hurdle. Nature Reviews Cancer, 2012, 12, 376-377.	28.4	15
9	ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression?. Cell Cycle, 2004, 3, 595-598.	2.6	14
10	HIF switch. Nature Reviews Cancer, 2011, 11, 391-391.	28.4	14
11	ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?. Cell Cycle, 2004, 3, 597-600.	2.6	14
12	Finding a rare variant. Nature Reviews Cancer, 2012, 12, 1-1.	28.4	11
13	All eyes on YAP1. Nature Reviews Cancer, 2014, 14, 515-515.	28.4	11
14	Pushing pancreatic cancer to take off. Nature Reviews Cancer, 2012, 12, 739-739.	28.4	10
15	Signalling in transit. Nature Reviews Cancer, 2012, 12, 5-5.	28.4	10
16	Means of resistance. Nature Reviews Cancer, 2013, 13, 607-607.	28.4	10
17	Teaching old macrophages new tricks. Nature Reviews Cancer, 2013, 13, 753-753.	28.4	10
18	Fibroblast co-conspirators. Nature Reviews Cancer, 2011, 11, 759-759.	28.4	9

#	Article	IF	CITATIONS
19	Dendritic cell switch. Nature Reviews Cancer, 2012, 12, 231-231.	28.4	9
20	APC restores order. Nature Reviews Cancer, 2015, 15, 454-455.	28.4	9
21	Primed for a response. Nature Reviews Cancer, 2015, 15, 258-259.	28.4	9
22	Cancer stem cell knockout. Nature Reviews Cancer, 2014, 14, 452-453.	28.4	8
23	A circuitous way to target p53. Nature Reviews Cancer, 2015, 15, 318-319.	28.4	8
24	Different roads to inactivation. Nature Reviews Cancer, 2009, 9, 610-611.	28.4	7
25	Field effect. Nature Reviews Cancer, 2012, 12, 508-509.	28.4	7
26	Endothelial cells create a niche. Nature Reviews Cancer, 2014, 14, 298-298.	28.4	7
27	Direct hit on mutant RAS. Nature Reviews Cancer, 2014, 14, 8-9.	28.4	7
28	Driving force. Nature Reviews Cancer, 2011, 11, 539-539.	28.4	6
29	Opposing forces in invasion. Nature Reviews Cancer, 2011, 11, 625-625.	28.4	6
30	Dynamic interactions. Nature Reviews Cancer, 2012, 12, 378-379.	28.4	6
31	BETting on epigenetic therapy. Nature Reviews Cancer, 2014, 14, 385-385.	28.4	6
32	Feed it forward. Nature Reviews Cancer, 2011, 11, 461-461.	28.4	5
33	New connections. Nature Reviews Cancer, 2012, 12, 321-321.	28.4	5
34	Navigating uncharted territory. Nature Reviews Cancer, 2012, 12, 151-151.	28.4	5
35	Easily moulded. Nature Reviews Cancer, 2013, 13, 519-519.	28.4	5
36	PTEN surprise. Nature Reviews Cancer, 2013, 13, 520-520.	28.4	5

#	Article	IF	CITATIONS
37	Hippo promotes microRNA processing. Nature Reviews Cancer, 2014, 14, 217-217.	28.4	5
38	Place your BETs. Nature Reviews Cancer, 2015, 15, 638-638.	28.4	5
39	Editing changes the meaning. Nature Reviews Cancer, 2012, 12, 797-797.	28.4	4
40	Combinations that work. Nature Reviews Cancer, 2012, 12, 231-231.	28.4	4
41	Destroying leukaemia stem cell habitats. Nature Reviews Cancer, 2013, 13, 821-821.	28.4	4
42	Making connections. Nature Reviews Cancer, 2013, 13, 222-223.	28.4	4
43	Coming in waves. Nature Reviews Cancer, 2013, 13, 379-379.	28.4	4
44	A clearer pathway view. Nature Reviews Cancer, 2014, 14, 156-157.	28.4	4
45	A cooperative tumour cell community. Nature Reviews Cancer, 2014, 14, 294-294.	28.4	4
46	Untangling the role of progesterone receptors. Nature Reviews Cancer, 2015, 15, 456-456.	28.4	4
47	Super-enhanced. Nature Reviews Cancer, 2015, 15, 4-5.	28.4	4
48	Cytokine cues. Nature Reviews Cancer, 2011, 11, 690-690.	28.4	3
49	Catabolic effects. Nature Reviews Cancer, 2011, 11, 757-757.	28.4	3
50	Epigenetic therapy gains momentum. Nature Reviews Cancer, 2012, 12, 799-799.	28.4	3
51	Tumours have a lot of nerve. Nature Reviews Cancer, 2013, 13, 608-609.	28.4	3
52	Elongation is essential. Nature Reviews Cancer, 2014, 14, 765-765.	28.4	3
53	Stressed to bits. Nature Reviews Cancer, 2015, 15, 320-320.	28.4	3
54	Order matters. Nature Reviews Cancer, 2015, 15, 196-197.	28.4	3

SARAH E SETON-ROGERS

#	Article	IF	CITATIONS
55	MYC maintains high-fidelity splicing. Nature Reviews Cancer, 2015, 15, 385-385.	28.4	3
56	A matter of timing. Nature Reviews Cancer, 2015, 15, 256-257.	28.4	3
57	An exhausting metabolic competition. Nature Reviews Cancer, 2015, 15, 573-573.	28.4	3
58	Model refinement. Nature Reviews Cancer, 2015, 15, 511-511.	28.4	3
59	One of these things is not like the others. Nature Reviews Cancer, 2016, 16, 5-5.	28.4	3
60	Flexible flux. Nature Reviews Cancer, 2011, 11, 621-621.	28.4	2
61	Layers of regulation. Nature Reviews Cancer, 2011, 11, 689-689.	28.4	2
62	Recharging with COCO. Nature Reviews Cancer, 2012, 12, 655-655.	28.4	2
63	Transforming fusions induce aneuploidy. Nature Reviews Cancer, 2012, 12, 585-585.	28.4	2
64	Mutational consequences. Nature Reviews Cancer, 2012, 12, 450-451.	28.4	2
65	Merlin and ezrin get organized. Nature Reviews Cancer, 2013, 13, 76-76.	28.4	2
66	An accommodating host. Nature Reviews Cancer, 2013, 13, 145-145.	28.4	2
67	Two steps ahead. Nature Reviews Cancer, 2013, 13, 383-383.	28.4	2
68	A pre-leukaemic reservoir. Nature Reviews Cancer, 2014, 14, 212-212.	28.4	2
69	A clearer pathway view. Nature Reviews Drug Discovery, 2014, 13, 177-177.	46.4	2
70	Uncovering new functions of PI3K mutations. Nature Reviews Cancer, 2014, 14, 766-767.	28.4	2
71	Source influences function. Nature Reviews Cancer, 2014, 14, 705-705.	28.4	2
72	A better mimic. Nature Reviews Cancer, 2014, 14, 75-75.	28.4	2

#	Article	IF	CITATIONS
73	Chromatin reorganization on a 'mega' scale. Nature Reviews Genetics, 2015, 16, 499-499.	16.3	2
74	From the editors. Nature Reviews Cancer, 2006, 6, 573-573.	28.4	1
75	Model building. Nature Reviews Cancer, 2011, 11, 387-387.	28.4	1
76	Location, location, location. Nature Reviews Cancer, 2011, 11, 462-463.	28.4	1
77	Another tool in the BCR–ABL kit?. Nature Reviews Cancer, 2011, 11, 833-833.	28.4	1
78	Lines of communication. Nature Reviews Cancer, 2012, 12, 580-581.	28.4	1
79	Layered regulation. Nature Reviews Cancer, 2012, 12, 737-737.	28.4	1
80	Tumour cells in reverse. Nature Reviews Cancer, 2012, 12, 794-794.	28.4	1
81	What's the alternative?. Nature Reviews Cancer, 2012, 12, 80-81.	28.4	1
82	A powerful model. Nature Reviews Cancer, 2013, 13, 8-9.	28.4	1
83	Seeing the big picture. Nature Reviews Cancer, 2013, 13, 683-683.	28.4	1
84	ALL-important mutations. Nature Reviews Cancer, 2013, 13, 151-151.	28.4	1
85	Double trouble. Nature Reviews Cancer, 2013, 13, 6-7.	28.4	1
86	Fuelling the debate. Nature Reviews Cancer, 2013, 13, 223-223.	28.4	1
87	Methylation reboot. Nature Reviews Cancer, 2013, 13, 292-292.	28.4	1
88	At the starting line. Nature Reviews Cancer, 2013, 13, 296-297.	28.4	1
89	Change in schedule. Nature Reviews Cancer, 2014, 14, 153-153.	28.4	1
90	Competition can be a good thing. Nature Reviews Cancer, 2014, 14, 381-381.	28.4	1

#	Article	IF	CITATIONS
91	Notch blocks bladder tumorigenesis. Nature Reviews Cancer, 2014, 14, 649-649.	28.4	1
92	Feeding the beast. Nature Reviews Cancer, 2015, 15, 134-134.	28.4	1
93	Mutant relationships. Nature Reviews Cancer, 2015, 15, 135-135.	28.4	1
94	Changing shape. Nature Reviews Cancer, 2015, 15, 71-71.	28.4	1
95	Primed for a response. Nature Reviews Drug Discovery, 2015, 14, 312-312.	46.4	1
96	Building bridges. Nature Reviews Cancer, 2015, 15, 199-199.	28.4	1
97	Promoting tolerance. Nature Reviews Immunology, 2010, 10, 292-292.	22.7	0
98	Putting the brakes on lipid loss. Nature Reviews Cancer, 2011, 11, 536-536.	28.4	0
99	Suppressive EPH-ect. Nature Reviews Cancer, 2011, 11, 829-829.	28.4	0
100	Domino effect. Nature Reviews Cancer, 2012, 12, 506-506.	28.4	0
101	The new normal. Nature Reviews Cancer, 2012, 12, 660-661.	28.4	0
102	Pump up the volume. Nature Reviews Cancer, 2012, 12, 583-583.	28.4	0
103	Scheduled delivery. Nature Reviews Cancer, 2012, 12, 155-155.	28.4	0
104	No cohesion for cohesin's role. Nature Reviews Cancer, 2013, 13, 825-825.	28.4	0
105	Improved detection. Nature Reviews Cancer, 2013, 13, 150-151.	28.4	0
106	Metabolic block. Nature Reviews Cancer, 2013, 13, 440-441.	28.4	0
107	Taking it all in. Nature Reviews Cancer, 2013, 13, 438-438.	28.4	0
108	Two might not be better. Nature Reviews Cancer, 2014, 14, 646-646.	28.4	0

#	Article	IF	CITATIONS
109	Carving out a niche. Nature Reviews Cancer, 2014, 14, 516-516.	28.4	Ο
110	Working in groups. Nature Reviews Cancer, 2014, 14, 645-645.	28.4	0
111	Fine-tuning metabolism. Nature Reviews Cancer, 2014, 14, 705-705.	28.4	0
112	Order matters. Nature Reviews Genetics, 2015, 16, 193-193.	16.3	0
113	An influential delivery. Nature Reviews Cancer, 2015, 15, 386-386.	28.4	0
114	Stress management by the FA pathway. Nature Reviews Cancer, 2015, 15, 699-699.	28.4	0
115	Exploring origins and evolution. Nature Reviews Cancer, 2015, 15, 68-69.	28.4	Ο
116	Chromatin reorganization on a 'mega' scale. Nature Reviews Cancer, 2015, 15, 513-513.	28.4	0
117	Tracking early tumour cells. Nature Reviews Cancer, 2016, 16, 69-69.	28.4	0